Biogen CEO Michel Vounatsos told CNBC that the list price of $56,000 per year for the company's FDA-approved Alzheimer's disease drug aducanumab is "fair."
https://ift.tt/3w29QoY
Powered by Blogger.
Social Counter
Search This Blog
Popular Posts
-
Generic Mad Money Contemplate https://ift.tt/3itGUlU
-
The Senate on Tuesday passed one of the largest industrial bills in U.S. history in a bipartisan effort to ensure the U.S. remains competiti...
-
Since November, shares of IndusInd Bank have gained 56 per cent outperforming the 24 per cent rally in the Bank Nifty index, a gauge of bank...
-
Bihar: Over 1 mn affected in floods, 7 killedThe government stated in the daily flood bulletin that 10,61,152 people have been affected due ...
-
GameStop soars as activist investor wants to play GameStop Corp.’s largest individual investor upped his stake and has plans for the co...
-
The banks were identified in reports as having allegedly moved large sums of illicit funds over a period of nearly two decades. https://if...
-
Guy Rosen, Facebook's vice president of integrity, said Covid-19 vaccine hesitancy among users in the U.S. has declined by 50%. https:...
-
Biden "understands the importance of cooperation among nations,'' said former Colombian president and Nobel Peace Prize winner ...
-
In the first quarter, announced deals for global investment in electric car batteries exceeded that for all of 2020, according to Fitch Solu...
-
https://ift.tt/3AObaxq
Popular Posts
Recovery may strengthen further in H2, says Finance Ministry
December 11, 2021
States ping banks to adopt contactless solutions
September 24, 2020
Recent Posts
3/recent/post-list
Featured Posts
Recent in Recipes
3/Food/post-list
Created By eaadhar | Distributed By Blogger Themes
0 Comments